Pheochromocytoma and paraganglioma (PPGL) · line 1 · Cabozantinib monotherapy (metastatic non-MIBG-avid pheochromocytoma/paraganglioma, alternative to sunitinib)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-CABOZANTINIB-PHEO |
| ID | IND-PHEO-METASTATIC-1L-CABOZANTINIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-07-11 |
| Diseases | DIS-PHEOCHROMOCYTOMA |
| Sources | SRC-NCCN-NET-2025 |
Notes
Coverage-enabling metastatic-disease indication for DIS-PHEOCHROMOCYTOMA, alternative non-MIBG-avid systemic branch. Reuses DRUG-CABOZANTINIB. Deliberately cited only via the existing SRC-NCCN-NET-2025 guideline rather than a specific cabozantinib-in- PPGL trial Source, because no specific trial name/citation could be confirmed with enough confidence to author a new Source stub for it (unlike sunitinib's FIRSTMAPPP, which the Disease narrative names explicitly and which was independently verified via PubMed this session). Requires medical oncology co-lead signoff before clinical publication.
Used By
Algorithms
ALGO-PHEO-1L- ALGO-PHEO-1L
Disease
DIS-PHEOCHROMOCYTOMA- Pheochromocytoma and paraganglioma (PPGL)
Indication
IND-PHEO-METASTATIC-1L-MIBG- IND-PHEO-METASTATIC-1L-MIBGIND-PHEO-METASTATIC-1L-SUNITINIB- IND-PHEO-METASTATIC-1L-SUNITINIB